KRAS and acute myeloid leukemia: Among common AML mutations, ZNF740 was found to be expressed at lower levels in AML subtypes associated with poor venetoclax response, such as those with KRAS mutations [7], and at higher levels in subtypes with better venetoclax response, such as NPM1 mutations [18] (Supplementary Fig. 1E).